Juergen Armbrecht

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

H.‐H. Parving, Barry M. Brenner, John J.V. McMurray et al. · Nephrology Dialysis Transplantation · 2009 · 307 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium.

Juergen Armbrecht, Denis B. Buxton, H R Schelbert · Circulation · 1990 · 178 citations

Medicine, Nuclear Medicine, Pharmacology +17

Regional myocardial oxygen consumption determined noninvasively in humans with [1-11C]acetate and dynamic positron tomography.

Juergen Armbrecht, Denis B. Buxton, Richard C. Brunken et al. · Circulation · 1989 · 157 citations · Full text

Medicine, Nuclear Medicine, Physiology +14

Direct Renin Inhibition in Addition to or as an Alternative to Angiotensin Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale and Design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) Study

Henry Krum, Barry M. Massie, William T. Abraham et al. · European Journal of Heart Failure · 2010 · 127 citations · Full text

Medicine, Cardiology, Pharmacology +16

Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension

Stephen J. Nicholls, George L. Bakris, John J.P. Kastelein et al. · JAMA · 2013 · 73 citations

Medicine, Pharmacology, Pharmacotherapy +17